Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Recruiting
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy.
2025-522771-28-00· Phase 3· Inmunotek S.L.· Source
Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)
2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source
Recruiting
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549· Phase 3· Ipsen· Source
Active, not recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
2025-522440-41-00· Phase 2· Bluefin Biomedicine Inc.· Source
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390· Phase 2· Pfizer· Source
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· Phase 3· AbbVie· Source
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168· Ipsen· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· Phase 3· Ipsen· Source
Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Active, not recruiting
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362· Phase 2· Ipsen· Source
Active, not recruiting
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Recruiting
Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry
NCT05673681· Fundación Academia Española de Dermatología· Source
Contact: Ángeles Flórez
Active, not recruiting
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
NCT04862286· Phase 3· AbbVie· Source
Active, not recruiting
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665· Phase 3· Ipsen· Source
Active, not recruiting
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· Phase 3· Madrigal Pharmaceuticals Inc.· Source
Recruiting
Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
NCT05674695· Fundación Academia Española de Dermatología· Source
Contact: Ángeles Flórez
Active, not recruiting
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· Phase 3· Fundacion PETHEMA· Source